Published in Ann Intern Med on March 05, 2013
Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer (2016) 2.91
Impact of hepatitis C virus eradication on hepatocellular carcinogenesis. Cancer (2015) 2.67
Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology (2014) 2.34
Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population. JAMA Intern Med (2016) 1.77
Hepatocarcinogenesis in chronic hepatitis C patients achieving a sustained virological response to interferon: significance of lifelong periodic cancer screening for improving outcomes. J Gastroenterol (2013) 1.65
Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice. Clin Gastroenterol Hepatol (2015) 1.45
The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. J Viral Hepat (2013) 1.37
Chemopreventive strategies in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol (2013) 1.36
Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C? Antiviral Res (2014) 1.17
Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology (2016) 1.17
Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition. Cancer Cell (2016) 1.14
Hepatitis C, stigma and cure. World J Gastroenterol (2013) 1.13
The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations. J Clin Exp Hepatol (2014) 1.12
Current management of hepatocellular carcinoma. Gastroenterol Hepatol (N Y) (2014) 1.10
Recommendations on hepatitis C screening for adults. CMAJ (2017) 1.07
Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma. Semin Cancer Biol (2014) 1.04
Overview and recent trends of systematic reviews and meta-analyses in hepatology. Clin Mol Hepatol (2014) 1.04
Perceptions of drug users regarding hepatitis C screening and care: a qualitative study. Harm Reduct J (2013) 1.01
Hepatocellular carcinoma in a large medical center of China over a 10-year period: evolving therapeutic option and improving survival. Oncotarget (2015) 1.00
Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals. BMC Med (2017) 0.96
Hepatocellular carcinoma: a review. J Hepatocell Carcinoma (2016) 0.95
Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation. J Hepatol (2016) 0.95
Molecular mechanism and treatment of viral hepatitis-related liver fibrosis. Int J Mol Sci (2014) 0.95
Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits. BMC Infect Dis (2015) 0.94
Oxidative stress and hepatic Nox proteins in chronic hepatitis C and hepatocellular carcinoma. Free Radic Biol Med (2014) 0.94
Previous exposure to HCV among persons born during 1945-1965: prevalence and predictors, United States, 1999-2008. Am J Public Health (2014) 0.94
Human viruses and cancer. Viruses (2014) 0.92
Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade. World J Hepatol (2015) 0.91
Hepatitis C Virus Infection in Patients Undergoing Hematopoietic Cell Transplantation in the Era of Direct-Acting Antiviral Agents. Biol Blood Marrow Transplant (2015) 0.91
Prevention of hepatocellular carcinoma in chronic viral hepatitis B and C infection. World J Gastroenterol (2013) 0.89
Impaired expression of type I and type II interferon receptors in HCV-associated chronic liver disease and liver cirrhosis. PLoS One (2014) 0.89
Genetics Variants and Serum Levels of MHC Class I Chain-related A in Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients Post Antiviral Treatment. EBioMedicine (2016) 0.88
Hepatitis C cirrhosis: New perspectives for diagnosis and treatment. World J Hepatol (2015) 0.87
Screening guidelines for non-AIDS defining cancers in HIV-infected individuals. Curr Opin Oncol (2013) 0.87
SASLT guidelines: Update in treatment of Hepatitis C virus infection. Saudi J Gastroenterol (2016) 0.85
Management of treatment-naïve chronic hepatitis C genotype 1 patients: a cost-effectiveness analysis of treatment options. J Viral Hepat (2014) 0.85
Molecular classification of hepatocellular carcinoma: potential therapeutic implications. Hepat Oncol (2015) 0.84
MICA SNPs and the NKG2D system in virus-induced HCC. J Gastroenterol (2014) 0.83
Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis. Hepatology (2016) 0.82
Current management of patients with hepatocellular carcinoma. World J Hepatol (2015) 0.82
Prediction of the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients after Sustained Virological Response by Aspartate Aminotransferase to Platelet Ratio Index. Gut Liver (2016) 0.82
Pretreatment glucose status determines HCC development in HCV patients with mild liver disease after curative antiviral therapy. Medicine (Baltimore) (2016) 0.81
Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality. BMC Gastroenterol (2014) 0.81
New treatments for hepatitis C virus (HCV): scope for preventing liver disease and HCV transmission in England. J Viral Hepat (2016) 0.81
Molecular oncology testing in resource-limited settings. J Mol Diagn (2014) 0.81
Recent advances in management of the HIV/HCV coinfected patient. Future Virol (2016) 0.81
Liver cancer: Effect of HCV clearance with direct-acting antiviral agents on HCC. Nat Rev Gastroenterol Hepatol (2016) 0.81
Functional polymorphisms of TLR8 are associated with hepatitis C virus infection. Immunology (2014) 0.80
Diffusion of information throughout the host interactome reveals gene expression variations in network proximity to target proteins of hepatitis C virus. PLoS One (2014) 0.80
Hepatitis C vaccine. Need of the hour. Hum Vaccin Immunother (2014) 0.80
Hepatitis C-related liver cirrhosis - strategies for the prevention of hepatic decompensation, hepatocarcinogenesis, and mortality. World J Gastroenterol (2014) 0.80
Strategies for treating chronic HCV infection in patients with cirrhosis: latest evidence and clinical outcomes. Ther Adv Chronic Dis (2015) 0.80
Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol (2016) 0.80
HEPATOCELLULAR CARCINOMA IN A NON-CIRRHOTIC PATIENT WITH SUSTAINED VIROLOGICAL RESPONSE AFTER HEPATITIS C TREATMENT. Rev Inst Med Trop Sao Paulo (2015) 0.79
APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. Hepatol Int (2016) 0.79
Scotomas in molecular virology and epidemiology of hepatitis C virus. World J Gastroenterol (2013) 0.79
Nonzero Risk of Hepatocellular Carcinoma Even after Sustained Virological Response. Gut Liver (2016) 0.78
Interaction of human tumor viruses with host cell surface receptors and cell entry. Viruses (2015) 0.78
A comprehensive long-term prognosis of chronic hepatitis C patients with antiviral therapy: a meta-analysis of studies from 2008 to 2014. Hepat Mon (2015) 0.78
Hepatitis C: Treatment of difficult to treat patients. World J Hepatol (2015) 0.78
Challenges in managing hepatitis C virus infection in cancer patients. World J Gastroenterol (2014) 0.78
Antiviral natural products and herbal medicines. J Tradit Complement Med (2014) 0.78
Hepatitis C Virus Testing and Linkage to Care in North Carolina and South Carolina Jails, 2012-2014. Public Health Rep (2016) 0.77
Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States: The quality-adjusted cost of care. Medicine (Baltimore) (2016) 0.77
Bioinformatics analysis of hepatitis C virus genotype 2a-induced human hepatocellular carcinoma in Huh7 cells. Onco Targets Ther (2016) 0.77
Direct antiviral agent treatment of decompensated hepatitis C virus-induced liver cirrhosis. World J Gastrointest Pharmacol Ther (2015) 0.76
Improved Survival Among all Interferon-α-Treated Patients in HCV-002, a Veterans Affairs Hepatitis C Cohort of 2211 Patients, Despite Increased Cirrhosis Among Nonresponders. Dig Dis Sci (2016) 0.76
Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease. F1000Res (2016) 0.76
Surgical approach for hepatitis C virus-related hepatocellular carcinoma. World J Hepatol (2015) 0.76
Viral hepatitis and liver cancer. Philos Trans R Soc Lond B Biol Sci (2017) 0.75
Ribavirin contributes to eradicate hepatitis C virus through polarization of T helper 1/2 cell balance into T helper 1 dominance. World J Hepatol (2015) 0.75
Cost-Effectiveness of Risk Score-Stratified Hepatocellular Carcinoma Screening in Patients with Cirrhosis. Clin Transl Gastroenterol (2017) 0.75
Doing the math on hepatitis C virus treatment. J Hepatol (2016) 0.75
Effect of Treatment for CHC on Liver Disease Progression and Hepatocellular Carcinoma Development in African Americans. J Clin Transl Hepatol (2015) 0.75
A Cost-Utility Analysis of Different Antiviral Medicine Regimens in Patients With Chronic Hepatitis C Virus Genotype 1 Infection. Iran Red Crescent Med J (2016) 0.75
Pretreatment AKR1B10 expression predicts the risk of hepatocellular carcinoma development after hepatitis C virus eradication. World J Gastroenterol (2016) 0.75
Association of sustained virologic response with reduced progression to liver cirrhosis in elderly patients with chronic hepatitis C. Clin Interv Aging (2016) 0.75
Successful Interferon Therapy Reverses Enhanced Hepatic Progenitor Cell Activation in Patients with Chronic Hepatitis C. J Interferon Cytokine Res (2015) 0.75
A double-blind randomized controlled study to evaluate the efficacy of low-dose oral interferon-alpha in preventing hepatitis C relapse. J Interferon Cytokine Res (2013) 0.75
Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C. World J Hepatol (2017) 0.75
Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin. Clin Interv Aging (2016) 0.75
Potential Role of Hepatitis C Virus Alternate Reading Frame Protein in Negative Regulation of T-Bet Gene Expression. Inflammation (2015) 0.75
Personalized management of hepatocellular carcinoma based on molecular information: future prospects. Clin Liver Dis (Hoboken) (2015) 0.75
Diabetes mellitus increases the risk of hepatocellular carcinoma in treatment-naïve chronic hepatitis C patients in China. Medicine (Baltimore) (2017) 0.75
Hepatitis C Point-of-Care Screening in Retail Pharmacies in the United States. Gastroenterol Hepatol (N Y) (2017) 0.75
How much management is necessary? Sustaining the benefit of achieving a sustained virologic response to hepatitis C. J Gastroenterol (2014) 0.75
Neutrophil-to-lymphocyte ratio as a predictor of response to peginterferon plus ribavirin therapy for chronic hepatitis C. Dis Markers (2014) 0.75
Chronic hepatitis C virus infection and pathogenesis of hepatocellular carcinoma. Curr Opin Virol (2016) 0.75
De novo Hepatocellular Carcinoma after Liver Transplantation. J Clin Transl Hepatol (2015) 0.75
Prevention of Hepatocellular Carcinoma. Gastrointest Tumors (2016) 0.75
Hepatitis C in a New Era: A Review of Current Therapies. P T (2017) 0.75
TBX21 polymorphisms are associated with virus persistence in hepatitis C virus infection patients from a high-risk Chinese population. Eur J Clin Microbiol Infect Dis (2015) 0.75
Occurrence of hepatocellular carcinoma upon advanced liver fibrosis thirteen years after achieving sustained virological response to hepatitis C: how long surveillance should be maintained? Dig Dis Sci (2014) 0.75
The oncologic burden of hepatitis C virus infection: A clinical perspective. CA Cancer J Clin (2017) 0.75
Single nucleotide polymorphisms of toll-like receptor 7 in hepatitis C virus infection patients from a high-risk chinese population. Inflammation (2015) 0.75
Impact of hepatitis C oral therapy in portal hypertension. World J Gastroenterol (2017) 0.75
Drug Treatment for Chronic Hepatitis C Infection and Cancer Risk. Dtsch Arztebl Int (2017) 0.75
Prevalence of pks-positive Escherichia coli in Japanese patients with or without colorectal cancer. Gut Pathog (2017) 0.75
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (2008) 33.10
Grading quality of evidence and strength of recommendations. BMJ (2004) 26.08
GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol (2010) 11.77
GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol (2011) 10.02
Going from evidence to recommendations. BMJ (2008) 7.30
What is "quality of evidence" and why is it important to clinicians? BMJ (2008) 6.99
Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep (2012) 6.91
GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). J Clin Epidemiol (2011) 5.10
Hepatitis C virus testing of persons born during 1945-1965: recommendations from the Centers for Disease Control and Prevention. Ann Intern Med (2012) 4.29
The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med (2011) 3.80
GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol (2010) 3.60
GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol (2013) 3.58
GRADE guidelines 6. Rating the quality of evidence--imprecision. J Clin Epidemiol (2011) 3.54
GRADE guidelines: 5. Rating the quality of evidence--publication bias. J Clin Epidemiol (2011) 3.44
GRADE guidelines: 9. Rating up the quality of evidence. J Clin Epidemiol (2011) 3.30
GRADE guidelines: 7. Rating the quality of evidence--inconsistency. J Clin Epidemiol (2011) 3.02
GRADE guidelines: 8. Rating the quality of evidence--indirectness. J Clin Epidemiol (2011) 2.83
Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology (2012) 2.68
Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. Dig Liver Dis (2010) 1.96
GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. J Clin Epidemiol (2012) 1.90
HCV screening practices and prevalence in an MCO, 2000-2007. Am J Manag Care (2011) 1.51
U.S. multicenter pilot study of daily consensus interferon (CIFN) plus ribavirin for "difficult-to-treat" HCV genotype 1 patients. Dig Dis Sci (2011) 1.44
Primary care-based interventions are associated with increases in hepatitis C virus testing for patients at risk. Dig Liver Dis (2012) 1.14
The GRADE approach is reproducible in assessing the quality of evidence of quantitative evidence syntheses. J Clin Epidemiol (2013) 1.11
Low rates of hepatitis screening and vaccination of HIV-infected MSM in HIV clinics. Sex Transm Dis (2012) 1.05
An Evidence-based Guideline for the air medical transportation of prehospital trauma patients. Prehosp Emerg Care (2013) 1.02
Searching the MEDLINE literature database through PubMed: a short guide. Onkologie (2005) 1.02
An emerging consensus on grading recommendations? ACP J Club (2006) 1.01
Determinants of knowledge gain in evidence-based medicine short courses: an international assessment. Open Med (2010) 0.98
Models of community-based hepatitis B surface antigen screening programs in the U.S. and their estimated outcomes and costs. Public Health Rep (2011) 0.97
Potential role of safer injection facilities in reducing HIV and hepatitis C infections and overdose mortality in the United States. Drug Alcohol Depend (2011) 0.95
Uncertainties in baseline risk estimates and confidence in treatment effects. BMJ (2012) 0.95
Previous exposure to HCV among persons born during 1945-1965: prevalence and predictors, United States, 1999-2008. Am J Public Health (2014) 0.94
The Program Evaluation and Monitoring System: a key source of data for monitoring evidence-based HIV prevention program processes and outcomes. AIDS Educ Prev (2006) 0.94
Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care. World J Gastroenterol (2013) 0.93
Taxonomy for strengthening the identification of core elements for evidence-based behavioral interventions for HIV/AIDS prevention. Health Educ Res (2011) 0.92
Baseline levels of soluble CD14 and CD16+56- natural killer cells are negatively associated with response to interferon/ribavirin therapy during HCV-HIV-1 coinfection. J Infect Dis (2012) 0.88
An emerging consensus on grading recommendations? Evid Based Med (2006) 0.87
An evidence-based approach to patient selection for emergency department thoracotomy: A practice management guideline from the Eastern Association for the Surgery of Trauma. J Trauma Acute Care Surg (2015) 0.87
Genetically associated CD16(+)56(-) natural killer cell interferon (IFN)-αR expression regulates signaling and is implicated in IFN-α-induced hepatitis C virus decline. J Infect Dis (2012) 0.86
Reduced sexual risk behaviors among people living with HIV: Results from the Healthy Relationships Outcome Monitoring Project. AIDS Behav (2011) 0.85
Addendum: BOB CAT: A Large-Scale Review and Delphi Consensus for Management of Barrett's Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia. Am J Gastroenterol (2015) 0.84
Effectiveness of a risk screener in identifying hepatitis C virus in a primary care setting. Am J Public Health (2012) 0.84
Cervical spine collar clearance in the obtunded adult blunt trauma patient: a systematic review and practice management guideline from the Eastern Association for the Surgery of Trauma. J Trauma Acute Care Surg (2015) 0.83
Salmonella kingabwa infections and lizard contact, United States, 2005. Emerg Infect Dis (2007) 0.82
Moving from evidence to developing recommendations in guidelines: article 11 in Integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report. Proc Am Thorac Soc (2012) 0.82
Hepatitis C virus-related knowledge and willingness to receive treatment among patients on methadone maintenance. J Addict Med (2014) 0.81
Data to guide the "test and treat era" of hepatitis C. Gastroenterology (2012) 0.81
Ultrathin esophagoscopy in screening for Barrett's esophagus at a Veterans Administration Hospital: easy access does not lead to referrals. Am J Gastroenterol (2008) 0.81
Physician nonadherence with a hepatitis C screening program. Qual Manag Health Care (2013) 0.80
Targeted hepatitis C antibody testing interventions: a systematic review and meta-analysis. Eur J Epidemiol (2014) 0.80
An Evidence-based Guideline for prehospital analgesia in trauma. Prehosp Emerg Care (2013) 0.79
Implementation and evaluation of a multicomponent quality improvement intervention to improve efficiency of hepatitis C screening and diagnosis. Jt Comm J Qual Patient Saf (2014) 0.79
Risk factors for acute gastrointestinal bleeding following myocardial infarction in veteran patients who are prescribed clopidogrel. J Dig Dis (2014) 0.79
A case study of a real-time evaluation of the risk of disease transmission associated with a failure to follow recommended sterilization procedures. Antimicrob Resist Infect Control (2014) 0.79
Report on the 1st international workshop on procedures for the development of evidence-based vaccination recommendations, Berlin, Germany, 22-23 November 2010. Vaccine (2011) 0.79
An Electronic Health Record-based Intervention to Promote Hepatitis C Virus Testing Among Adults Born Between 1945 and 1965: A Cluster-randomized Trial. Med Care (2017) 0.79
Incorporating considerations of cost-effectiveness, affordability, and resource implications in guideline development: article 6 in Integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report. Proc Am Thorac Soc (2012) 0.78
Management of penetrating extraperitoneal rectal injuries: An Eastern Association for the Surgery of Trauma practice management guideline. J Trauma Acute Care Surg (2016) 0.77
News from the CDC: Translating science into HCV infection screening recommendations. Transl Behav Med (2011) 0.75
Response. Chest (2013) 0.75
Evaluating a hepatitis c quality gap: missed opportunities for HCV-related cares. Am J Manag Care (2014) 0.75
Hepatitis C virus testing of persons born during 1945-1965. In response. Ann Intern Med (2013) 0.75
[Procedures and methods of benefit assessments for medicines in Germany - a comment - letter no. 2]. Dtsch Med Wochenschr (2009) 0.75
[A Reporting Tool for Practice Guidelines in Health Care: The RIGHT Statement]. Z Evid Fortbild Qual Gesundhwes (2017) 0.75
The AGA institute process for developing clinical practice guidelines part one: grading the evidence. Clin Gastroenterol Hepatol (2013) 0.75
Procedures and methods of benefit assessments for medicines in Germany: give the child a name. Eur J Health Econ (2009) 0.75
[Report from the United States: an international work group develops a united system for evaluating recommendations]. Z Arztl Fortbild Qualitatssich (2006) 0.75